 Merck & Co. unveiled an unusual plan to collaborate with three rivals—Pfizer Inc., Amgen Inc. and Incyte Corp.—to study how Merck's immunotherapy cancer drug performs in combination with other treatments. . The partnerships underscore the industry's intensifying competition in immunotherapy drugs, which are designed to unleash the patient's immune system to fight cancer. Merck, Bristol-Myers Squibb Co. and Roche Holding Ltd. are among the companies developing immunotherapy drugs for what analysts say could be a multibillion-dollar...
  